Actinium Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ATNM NYSE American 2836 www.actiniumpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Actinium Pharmaceuticals, Inc.

Life Sciences Investor Forum: Now Available for Online Viewing - Jun 13th, 2025 6:35 am
Life Sciences Investor Forum Agenda Announced for June 11th-12th - Jun 10th, 2025 12:38 pm
Actinium: Q1 Earnings Snapshot - May 9th, 2025 3:33 pm
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center - May 6th, 2025 6:45 am
Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting - Apr 28th, 2025 6:30 am
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting - Apr 28th, 2025 6:00 am
Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225 - Mar 27th, 2025 6:45 am
Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives - Mar 27th, 2025 5:30 am
Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today - Mar 26th, 2025 6:45 am
Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program - Mar 25th, 2025 4:00 am
Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities - Mar 24th, 2025 2:15 pm
Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy - Mar 20th, 2025 6:00 am
Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025 - Mar 19th, 2025 6:30 am
Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination - Mar 19th, 2025 6:11 am
Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO® - Mar 18th, 2025 6:00 am
Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia - Mar 17th, 2025 6:50 am
Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference - Mar 12th, 2025 6:00 am
Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML - Mar 11th, 2025 6:30 am
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 - Nov 18th, 2024 6:00 am
Actinium: Q3 Earnings Snapshot - Nov 14th, 2024 5:02 pm